Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleximenib, Venetoclax and Azacitidine in Newly Diagnosed AML
NCT06852222Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of bleximenib in acute myeloid leukemia (AML), sponsored by Janssen Pharmaceutical. Started Jun 2025; status: recruiting.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06852222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852222.